GO:0019432 triglyceride biosynthetic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0019432 (triglyceride biosynthetic process) describes the biochemical routes that build triglycerides, the main storage form of metabolic energy.
• Triglyceride synthesis protects cells from fatty acid-induced lipotoxicity by safely storing excess fatty acids.
• The pathway is central to hepatic very-low-density lipoprotein (VLDL) production and systemic lipid transport.
• Triglyceride-rich lipoproteins are assembled intracellularly and remodeled in the circulation, linking the pathway to cardiometabolic disease.
• Adipose tissue dynamically stores and mobilizes triglycerides through the action of lipases such as ATGL.
• CRISPR knockout, point-mutation, knock-in and overexpression models enable causal testing of triglyceride synthesis genes in vitro and in vivo.
Description
Triglycerides (triacylglycerols) are neutral lipids composed of a glycerol backbone esterified with three fatty acids. The Gene Ontology term GO:0019432, triglyceride biosynthetic process, is defined as the chemical reactions and pathways resulting in the formation of a triglyceride, any triester of glycerol. This process is fundamental to energy storage, membrane lipid homeostasis and systemic lipid transport, and it is conserved from yeast to humans. In the liver, triglyceride synthesis is tightly coupled to the production and secretion of triglyceride-rich lipoproteins, which distribute fatty acids to peripheral tissues. In adipose tissue, triglyceride synthesis and breakdown are reciprocally regulated to match energy supply and demand. For researchers, GO:0019432 provides a structured framework for interpreting lipidomic, transcriptomic and genetic data. Perturbations in triglyceride biosynthesis are observed in fatty liver disease, insulin resistance, dyslipidemia and lipotoxicity, making the pathway a frequent target of functional genomics studies. Because triglycerides also participate in inflammatory signaling and macrophage biology, the pathway intersects with immunometabolism and atherosclerosis research. This article summarizes the definition, mechanism, key genes, disease links and experimental methods relevant to GO:0019432, with an emphasis on how CRISPR-based cell models can be used to dissect causal gene function.
triglyceride biosynthetic process At A Glance
| GO ID | GO:0019432 |
|---|---|
| GO term | triglyceride biosynthetic process |
| Ontology | biological_process |
| Definition | The chemical reactions and pathways resulting in the formation of a triglyceride, any triester of glycerol. |
| Synonyms | triacylglycerol biosynthesis; triacylglycerol biosynthetic process; triglyceride anabolism; triglyceride biosynthesis; triglyceride formation; triglyceride synthesis |
| Major function | Synthesis of triglycerides for energy storage, lipoprotein assembly and lipid homeostasis |
| Related processes | Fatty acid activation, glycerolipid metabolism, lipoprotein assembly and secretion |
| Cellular context | Endoplasmic reticulum and lipid droplet-associated membranes |
| Disease relevance | Fatty liver disease, dyslipidemia, insulin resistance, lipotoxicity and atherosclerosis |
What Is GO:0019432?
GO:0019432 (triglyceride biosynthetic process) is a biological process ontology term describing the chemical reactions and pathways that result in the formation of a triglyceride, defined as any triester of glycerol. In practical terms, it covers the enzymatic steps that activate fatty acids, assemble the glycerol backbone and catalyze sequential acylation reactions to yield triacylglycerol. The term is synonymous with triacylglycerol biosynthesis, triglyceride synthesis and triglyceride formation.
Why Is triglyceride biosynthetic process Important in Cell Biology?
Triglyceride biosynthesis is a central node in energy metabolism and systemic lipid transport. It allows cells to convert potentially toxic fatty acids into inert storage lipids, thereby preventing lipotoxicity and maintaining membrane integrity. In the liver, the pathway supplies triglycerides for VLDL assembly, which is essential for distributing energy to peripheral tissues. In adipose tissue, the balance between triglyceride synthesis and lipolysis determines fat mass and systemic fatty acid flux. Dysregulation of this pathway contributes to metabolic disease, making GO:0019432 a high-value target for functional genomics and therapeutic research.
• Prevents fatty acid-induced lipotoxicity by storing excess fatty acids as inert triglycerides.
• Supports hepatic VLDL assembly and secretion, a key step in systemic lipid transport.
• Maintains energy homeostasis in adipose tissue through regulated storage and mobilization.
• Links to dyslipidemia and cardiometabolic risk via triglyceride-rich lipoproteins.
• Contributes to macrophage inflammatory responses through lipid droplet dynamics.
• Provides a mechanistic framework for interpreting lipidomic and transcriptomic data.
• Enables causal gene testing using CRISPR knockout and knock-in models.
• Serves as a target for drug discovery in fatty liver disease and insulin resistance.
• Connects cellular metabolism to whole-body lipid transport physiology.
• Offers biomarkers and pathway readouts for metabolic phenotyping.
What Happens During triglyceride biosynthetic process?
Fatty acid activation and glycerol backbone supply
In simple terms: The cell first prepares fatty acids and glycerol building blocks so they can be joined together.
Triglyceride synthesis begins with the activation of fatty acids to acyl-CoA derivatives and the availability of glycerol-3-phosphate. These precursors are derived from glycolysis, glyceroneogenesis or exogenous fatty acid uptake. The liver is a major site where fatty acids are channeled into triglyceride synthesis for storage or lipoprotein production. In adipose tissue, precursor supply is coordinated with hormonal signals that control fat storage and mobilization.
Sequential acylation of glycerol-3-phosphate
In simple terms: Enzymes add fatty acids one by one to a glycerol backbone to build the final triglyceride.
The core of GO:0019432 is the stepwise acylation of glycerol-3-phosphate, first to lysophosphatidic acid, then to phosphatidic acid, and subsequently to diacylglycerol and triacylglycerol. These reactions occur primarily at the endoplasmic reticulum and are catalyzed by acyltransferases and phosphatases. The pathway is conserved and essential for storing excess fatty acids as neutral lipids.
Lipid droplet formation and storage
In simple terms: Newly made triglycerides are packaged into lipid droplets, which act as cellular fat storage depots.
Once synthesized, triglycerides are sequestered into lipid droplets, dynamic organelles that store neutral lipids and regulate their release. Lipid droplet-associated proteins and lipases control the balance between storage and mobilization. In macrophages, triglyceride breakdown from lipid droplets regulates inflammatory responses, illustrating the signaling role of these storage pools. In adipocytes, adipose triglyceride lipase (ATGL) promotes fat mobilization, highlighting the reversible nature of triglyceride storage.
Assembly and secretion of triglyceride-rich lipoproteins
In simple terms: In the liver and intestine, triglycerides are packaged with proteins into particles that travel through the blood.
Hepatic triglyceride synthesis provides substrate for the assembly of very-low-density lipoproteins (VLDL), which transport lipids to peripheral tissues. Intracellular metabolism of triglyceride-rich lipoproteins involves lipolytic processing and remodeling, linking the biosynthetic pathway to systemic lipid transport. Plasma lipid transport depends on these particles, and their dysregulation is associated with cardiometabolic disease.
Integration with whole-body energy homeostasis
In simple terms: The pathway responds to the body's energy needs, storing fat when energy is abundant and releasing it when needed.
Triglyceride biosynthesis is not an isolated process; it is regulated by nutritional and hormonal signals that coordinate liver, adipose tissue and muscle. Fat cells store and release fatty acids in response to energy status, and the balance between synthesis and lipolysis determines circulating lipid levels. This integration ensures that triglycerides serve as a flexible energy buffer and a source of lipid precursors for other tissues.
Key Genes Involved in GO:0019432 triglyceride biosynthetic process
The following genes and proteins are established participants in or regulators of triglyceride biosynthesis and related lipid storage pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GPAT1 | Glycerol-3-phosphate acyltransferase; catalyzes the first committed step of glycerolipid synthesis | Target for hepatic steatosis and insulin resistance studies |
| AGPAT2 | Acylglycerol-3-phosphate acyltransferase; converts lysophosphatidic acid to phosphatidic acid | Linked to lipodystrophy and lipid storage disorders |
| LPIN1 | Phosphatidate phosphatase; generates diacylglycerol for triglyceride synthesis | Regulates lipid flux and metabolic gene expression |
| DGAT1 | Diacylglycerol acyltransferase; catalyzes the final step of triglyceride synthesis | Key enzyme for triglyceride storage and lipoprotein production |
| DGAT2 | Diacylglycerol acyltransferase; major isoform for hepatic triglyceride synthesis | Target for fatty liver disease and dyslipidemia |
| PNPLA2 (ATGL) | Adipose triglyceride lipase; mobilizes triglycerides from lipid droplets | Central to lipolysis and energy homeostasis |
| LPL | Lipoprotein lipase; hydrolyzes triglyceride-rich lipoproteins | Determines plasma triglyceride clearance |
| APOB | Apolipoprotein B; structural component of VLDL and LDL | Essential for triglyceride-rich lipoprotein assembly |
| APOC3 | Apolipoprotein C-III; inhibits lipoprotein lipase | Modulates plasma triglyceride levels |
| MTTP | Microsomal triglyceride transfer protein; loads lipids onto APOB | Required for VLDL assembly |
| CIDEC | Cell death-inducing DFFA-like effector C; lipid droplet fusion protein | Regulates lipid droplet size and storage |
| PLIN1 | Perilipin 1; coats lipid droplets and controls lipase access | Modulates lipolysis in adipocytes |
| FASN | Fatty acid synthase; provides fatty acids for triglyceride synthesis | Supports lipogenesis and storage |
| SCD1 | Stearoyl-CoA desaturase; generates monounsaturated fatty acids | Influences triglyceride composition and fluidity |
| PPARG | Peroxisome proliferator-activated receptor gamma; master regulator of adipogenesis | Controls adipose triglyceride storage |
| SREBF1 | Sterol regulatory element-binding transcription factor 1; promotes lipogenic gene expression | Regulates triglyceride synthesis transcriptionally |
| INSIG1 | Insulin-induced gene 1; regulates SREBP processing | Modulates lipogenic pathway activity |
| CIDEB | Cell death-inducing DFFA-like effector B; promotes lipid droplet expansion | Involved in hepatic VLDL lipidation |
How Is triglyceride biosynthetic process Regulated?
Triglyceride biosynthesis is regulated at multiple levels. Transcriptionally, the SREBP pathway controls the expression of lipogenic enzymes in response to insulin and nutrient status. Hormonal signals such as insulin promote fat storage in adipose tissue, while catecholamines and other lipolytic signals stimulate triglyceride breakdown. Post-translational regulation of lipases and lipid droplet proteins provides rapid control of storage and mobilization. In the liver, the pathway is also influenced by substrate availability, fatty acid oxidation and lipoprotein assembly demands. This multilayered regulation ensures that triglyceride synthesis matches whole-body energy requirements.
triglyceride biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DGAT1 | Fatty liver disease, dyslipidemia | Hepatocyte knockout and overexpression models |
| DGAT2 | Hepatic steatosis, hypertriglyceridemia | Liver-specific knockout mouse and CRISPR cell lines |
| PNPLA2 (ATGL) | Neutral lipid storage disease, lipolysis defects | Adipocyte knockout and point-mutation models |
| APOC3 | Hypertriglyceridemia, cardiovascular risk | Knockout and knock-in hepatocyte models |
| LPL | Hypertriglyceridemia, lipoprotein lipase deficiency | Endothelial and adipocyte knockout models |
Nonalcoholic fatty liver disease and hepatic steatosis
Excessive hepatic triglyceride synthesis and accumulation are hallmarks of fatty liver disease. The liver plays a central role in triglyceride metabolism, and dysregulation of this pathway contributes to steatosis and insulin resistance. Genetic and pharmacological studies targeting DGAT enzymes and other lipogenic genes have been used to dissect these mechanisms.
Dyslipidemia and cardiovascular disease
Triglyceride-rich lipoproteins are directly linked to cardiovascular risk. Impaired clearance or overproduction of these particles leads to hypertriglyceridemia, a risk factor for atherosclerosis. Plasma lipid transport mechanisms involving apolipoproteins and lipases are central to this process.
Lipotoxicity and metabolic stress
When triglyceride synthesis is insufficient, excess fatty acids can cause lipotoxicity and cellular dysfunction. Triglyceride accumulation can protect against fatty acid-induced lipotoxicity, indicating a buffering role for the pathway. This has implications for obesity, diabetes and organ-specific lipid stress.
Inflammation and macrophage biology
Lipid droplet triglyceride turnover regulates inflammatory responses in macrophages, linking triglyceride metabolism to innate immunity and atherosclerosis. This connection expands the disease relevance of GO:0019432 beyond classical metabolic disorders.
From triglyceride biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for triglyceride synthesis? | CRISPR knockout cell line (e.g., hepatocyte or adipocyte) |
| Does a specific amino acid change alter enzyme activity? | CRISPR point-mutation knock-in cell line |
| Does a disease-associated variant affect lipid storage? | CRISPR knock-in of the variant with lipidomic readouts |
| Where does the protein localize during triglyceride synthesis? | Tagged knock-in with fluorescent or epitope tag |
| Does overexpression increase triglyceride accumulation? | CRISPR overexpression or cDNA overexpression model |
| Which genes modify the pathway in a genome-wide context? | CRISPR library screening with lipid phenotype selection |
How to Study the triglyceride biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Triglyceride enzymatic assay | Total triglyceride content | Quantifying lipid accumulation in cells or liver |
| Lipid droplet staining | Number and size of lipid droplets | High-content imaging of storage phenotypes |
| RNA sequencing | Transcriptional changes in lipid genes | Identifying pathway regulators |
| Proteomics | Protein abundance and interactions | Mapping enzyme complexes in triglyceride synthesis |
| CRISPR knockout | Loss-of-function effects | Testing gene requirement for triglyceride synthesis |
| CRISPR knock-in | Variant or tag effects | Modeling disease variants or tracking proteins |
| CRISPR library screening | Genome-wide modifiers | Discovering novel regulators of lipid storage |
Lipidomic and biochemical assays
Triglyceride levels can be measured using enzymatic assays, thin-layer chromatography or mass spectrometry. These methods quantify total triglyceride content and fatty acid composition, providing direct readouts of pathway activity. In cell models, lipid droplet staining with neutral lipid dyes allows rapid assessment of storage.
Transcriptomic and proteomic profiling
RNA sequencing and proteomics can identify genes and proteins co-regulated with triglyceride biosynthesis. This is useful for discovering novel regulators and for interpreting CRISPR screen results. Pathway enrichment analysis using GO:0019432 helps contextualize hits within lipid metabolism.
Genetic perturbation with CRISPR
CRISPR knockout, point mutation, knock-in and overexpression models enable causal testing of candidate genes. These approaches can be combined with lipidomic readouts to determine whether a gene is required or sufficient for triglyceride synthesis. Library screening extends this to genome-wide discovery.
Imaging and live-cell analysis
Fluorescence microscopy of lipid droplets and tagged enzymes allows spatial and temporal analysis of triglyceride synthesis. Live-cell imaging can reveal droplet dynamics and protein localization during storage and mobilization. These methods complement biochemical assays.
How CRISPR Can Be Used to Study GO:0019432 triglyceride biosynthetic process
Knockout
CRISPR knockout of candidate genes such as DGAT1, DGAT2 or PNPLA2 can determine whether they are required for triglyceride synthesis or storage. Knockout cell lines are compared with wild-type controls using lipidomic and imaging readouts. This approach is widely used to validate pathway components.
Point Mutation
CRISPR point mutation introduces specific amino acid changes to test catalytic residues or disease-associated variants. This allows precise structure-function analysis of enzymes involved in triglyceride biosynthesis. Point-mutant models can reveal whether a variant alters enzyme activity or stability.
Knock-in
CRISPR knock-in can insert tags, reporters or disease variants at endogenous loci. Tagged knock-in models enable tracking of protein localization and interactions during triglyceride synthesis. Disease-variant knock-in models help establish causality in metabolic phenotypes.
Overexpression
CRISPR overexpression or cDNA overexpression can test whether increased gene dosage enhances triglyceride accumulation. This is useful for identifying sufficiency relationships in the pathway. Overexpression models complement loss-of-function studies.
How EDITGENE Supports triglyceride biosynthetic process Research
Researchers studying triglyceride biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in lipid storage, lipoprotein assembly or metabolic disease. EDITGENE provides CRISPR-based cell model services that enable precise genetic perturbation and functional readouts for GO:0019432 research.
Contact EDITGENE today to design your custom CRISPR model for triglyceride biosynthetic process research.
Frequently Asked Questions About triglyceride biosynthetic process
What is GO:0019432?
GO:0019432 is the Gene Ontology term for triglyceride biosynthetic process, defined as the chemical reactions and pathways resulting in the formation of a triglyceride, any triester of glycerol.
What genes are involved in triglyceride biosynthetic process?
Key genes include GPAT1, AGPAT2, LPIN1, DGAT1, DGAT2, PNPLA2, LPL, APOB, APOC3 and MTTP, among others.
Why is triglyceride synthesis important?
It stores excess fatty acids, prevents lipotoxicity and supports lipoprotein assembly and systemic lipid transport.
How is triglyceride biosynthesis regulated?
It is regulated transcriptionally by SREBP and hormonally by insulin and lipolytic signals, as well as post-translationally by lipases and lipid droplet proteins.
What diseases are linked to triglyceride biosynthesis?
Fatty liver disease, dyslipidemia, cardiovascular disease, lipotoxicity and inflammatory conditions are linked to this pathway.
How can CRISPR be used to study triglyceride synthesis?
CRISPR knockout, point mutation, knock-in and overexpression models allow causal testing of genes involved in triglyceride synthesis and storage.
What methods measure triglyceride levels in cells?
Enzymatic assays, mass spectrometry, thin-layer chromatography and lipid droplet staining are commonly used.
What is the role of DGAT in triglyceride synthesis?
DGAT enzymes catalyze the final step of triglyceride synthesis by transferring an acyl group to diacylglycerol.
How do lipid droplets relate to triglyceride biosynthesis?
Newly synthesized triglycerides are stored in lipid droplets, which regulate storage and mobilization.
Can triglyceride synthesis protect against lipotoxicity?
Yes, triglyceride accumulation can protect cells from fatty acid-induced lipotoxicity by sequestering excess fatty acids.
Conclusion
GO:0019432 (triglyceride biosynthetic process) is a fundamental biological process that governs energy storage, lipoprotein assembly and cellular lipid homeostasis. Its dysregulation is implicated in fatty liver disease, dyslipidemia, lipotoxicity and inflammation, making it a key area of metabolic research. Understanding the genes and mechanisms involved requires robust experimental models, and CRISPR-based approaches provide powerful tools for causal interrogation of the pathway. EDITGENE offers comprehensive CRISPR cell model and screening services to support researchers studying triglyceride biosynthesis and related metabolic diseases.
References
- 1. Alves-Bezerra M et al.. 2017. Triglyceride Metabolism in the Liver.. Compr Physiol 8(1):1-8 PMID: 29357123
- 2. Listenberger LL et al.. 2003. Triglyceride accumulation protects against fatty acid-induced lipotoxicity.. Proc Natl Acad Sci U S A 100(6):3077-82 PMID: 12629214
- 3. van Dierendonck XAMH et al.. 2022. Triglyceride breakdown from lipid droplets regulates the inflammatory response in macrophages.. Proc Natl Acad Sci U S A 119(12):e2114739119 PMID: 35302892
- 4. Kockx M et al.. 2018. Triglyceride-Rich Lipoproteins.. Cardiol Clin 36(2):265-275 PMID: 29609756
- 5. Zimmermann R et al.. 2004. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase.. Science 306(5700):1383-6 PMID: 15550674
- 6. Spector AA. 1984. Plasma lipid transport.. Clin Physiol Biochem 2(2-3):123-34 PMID: 6386279
- 7. Ramsay TG. 1996. Fat cells.. Endocrinol Metab Clin North Am 25(4):847-70 PMID: 8977049
- 8. Heeren J et al.. 2001. Intracellular metabolism of triglyceride-rich lipoproteins.. Curr Opin Lipidol 12(3):255-60 PMID: 11353327
